In a breakthrough for obesity treatment, the FDA has approved a higher dose of Novo Nordisk's weight loss drug, Wegovy. This new version, at 7.2 milligrams, aims to compete with Eli Lilly's Zepbound. Novo Nordisk expects to launch this dose in April, offering patients an additional option to achieve their weight loss goals. The higher dose has shown impressive results, with patients losing an average of 20.7% of their weight after 72 weeks in a phase three trial. This approval marks a significant step forward in the fight against obesity and provides hope for those seeking effective weight loss solutions. Learn more about this exciting development and how it could impact the market.

FDA approval weight loss obesity treatment Novo Nordisk Wegovy Eli Lilly Zepbound drug competition health medical breakthrough